Replies to post #198806 on Biotech Values

[DewDiligence]

MON FY2Q16 CC slides:

http://www.monsanto.com/investors/Documents/2016/2016.04.06_MON_Q2F16_Financial_Results.pdf

Bullish (IMO): US Treasury’s new anti-inversion regs probably rule out a MON merger with Bayer Crop Sciences or BASF.

[DewDiligence]

MON licenses CRISPR-Cpf1 IP from Broad Institute:

http://finance.yahoo.com/news/monsanto-announces-global-genome-editing-173000786.html

Monsanto Company announced today that it has reached a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR-Cpf1 genome-editing technology in agriculture.

The CRISPR-Cpf1 system represents an exciting advance in genome-editing technology, because it has potential to be a simpler and more precise tool for making targeted improvements in a cell's DNA when compared to the CRISPR-Cas9 system.

…Some of these benefits include greater flexibility in the method used to edit and in the locations where edits may occur. In addition, the smaller size of the CRISPR-Cpf1 system provides researchers with more flexibility to use the genome-editing technology across multiple crops.

Just in time for MON’s R&D update tomorrow (concurrent with FY1Q17 results). Financial terms were not disclosed.